Aptevo Therapeutics(DE:AP82)
€65,970.000.00 (0.00%)
DE:AP82
Aptevo Therapeutics earnings date
€65,970.00
At close:0.00 (0.00%)
Aptevo Therapeutics (AP82) Q3 2021 Earnings Report
0 Followers
DE:AP82 Q3 2021 EPS Results
- Actual EPS
- -EUR 42,950.61
- Consensus EPS
- -EUR 42,358.19
- Beat/Miss
- Missed by -EUR 592.42
- One Year Ago EPS
- -EUR 63,685.39
DE:AP82 Q3 2021 Revenue Results
- Actual Revenue
- EUR 2.82M
- Expected Revenue
- EUR 2.82M
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- +111.62%
Earnings Announcement Details
- Quarter
- Q3 2021
- Date
- 11/12/2021
- Time
- Before Open
- Conference Call
- Friday, November 12, 2021
DE:AP82 Upcoming Earnings
Aptevo Therapeutics's next earnings date is estimated for April 1, 2027, based on past reporting schedules.
Q3 2021 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2021 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2021 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:AP82 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 01, 2027 | 2026 (Q4) | ―- | -5.83 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -3.38-4.72 | -36.52 | 87.07% (+31.79) | |
| Aug 14, 2026 | 2026 (Q2) | -5.47-4.83 | -137.55 | 96.49% (+132.72) | |
| May 07, 2026 | 2026 (Q1) | -5.09-5.83 | -1437.75 | 99.59% (+1431.92) | |
| Mar 26, 2026 | 2025 (Q4) | ―1532.43 | -2927.9 | 152.34% (+4460.33) | |
| Nov 06, 2025 | 2025 (Q3) | -34.22-36.52 | -5816.51 | 99.37% (+5779.99) | |
| Aug 11, 2025 | 2025 (Q2) | -1362.43-137.55 | -20236.61 | 99.32% (+20099.05) | |
| May 15, 2025 | 2025 (Q1) | -1378.80-1437.75 | -120571.39 | 98.81% (+119133.64) | |
| Feb 14, 2025 | 2024 (Q4) | -2538.17-2927.90 | -162741.08 | 98.20% (+159813.18) | |
| Nov 07, 2024 | 2024 (Q3) | -6907.10-5816.51 | -266590.01 | 97.82% (+260773.50) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

